Skip to main content
. 2022 Sep 8;7(17):e161820. doi: 10.1172/jci.insight.161820

Figure 1. Direct-from-patient screening (DPS) of SN38.

Figure 1

(A) Dose-response curves of SN38 (TOPO1 inhibitor) against 11 patient samples (samples 101–111) and PHH. Cells were treated at 10 μM–10 nM with 2-fold serial dilution. The y axis shows normalized percentage survival calculated as ([positive control – drug response at a given dose]/[positive control – negative control]) × 100. The x axis shows the concentration in μM. Data are presented as mean ± SD (n = 3). (B) Dose-response curves of SN38 in the presence of increasing concentrations of navitoclax. Synergy screening was done on patient sample DPS 102. (C) Comparison of synergy models for SN38-navitoclax combo from B. NPS, normalized percentage survival.